Englewood Cliffs, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today reported its financial results for the third quarter 2021 and gave an update on recent progress in its business. Operating Highlights Entered sponsored research agreement with Columbia University to develop…


Previous articlePTSF84 – A Brief Check-in From Wonderland
Next articlePsychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results